-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Kiniksa Pharmaceuticals International, plc quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2017 to 2023.
- Kiniksa Pharmaceuticals International, plc Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $4.37M, a 305% increase year-over-year.
- Kiniksa Pharmaceuticals International, plc annual Deferred Income Tax Expense (Benefit) for 2023 was -$33.8M, a 81.8% increase from 2022.
- Kiniksa Pharmaceuticals International, plc annual Deferred Income Tax Expense (Benefit) for 2022 was -$185M, a 1686418% decline from 2021.
- Kiniksa Pharmaceuticals International, plc annual Deferred Income Tax Expense (Benefit) for 2021 was $11K, a 99.7% decline from 2020.
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)